IL326014A - Psma-targeting radioligand treatment regimen - Google Patents

Psma-targeting radioligand treatment regimen

Info

Publication number
IL326014A
IL326014A IL326014A IL32601426A IL326014A IL 326014 A IL326014 A IL 326014A IL 326014 A IL326014 A IL 326014A IL 32601426 A IL32601426 A IL 32601426A IL 326014 A IL326014 A IL 326014A
Authority
IL
Israel
Prior art keywords
psma
radioligand
targeting
treatment regimen
regimen
Prior art date
Application number
IL326014A
Other languages
Hebrew (he)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL326014A publication Critical patent/IL326014A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL326014A 2023-07-21 2024-07-19 Psma-targeting radioligand treatment regimen IL326014A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363514849P 2023-07-21 2023-07-21
PCT/IB2024/057048 WO2025022285A2 (en) 2023-07-21 2024-07-19 Psma-targeting radioligand treatment regimen

Publications (1)

Publication Number Publication Date
IL326014A true IL326014A (en) 2026-03-01

Family

ID=92458968

Family Applications (1)

Application Number Title Priority Date Filing Date
IL326014A IL326014A (en) 2023-07-21 2024-07-19 Psma-targeting radioligand treatment regimen

Country Status (5)

Country Link
KR (1) KR20260040237A (en)
CN (1) CN121604981A (en)
AU (1) AU2024298619A1 (en)
IL (1) IL326014A (en)
WO (1) WO2025022285A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024404739A1 (en) * 2023-12-18 2026-05-14 Fusion Pharmaceuticals Inc. Psma-targeted radiopharmaceuticals for treatment of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3456700A1 (en) 2013-10-18 2019-03-20 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
RS62274B1 (en) 2016-03-22 2021-09-30 Univ Johns Hopkins Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
SMT202400439T1 (en) 2017-12-11 2024-11-15 Univ Muenchen Tech Psma ligands for imaging and endoradiotherapy
AU2020299974A1 (en) 2019-07-02 2022-01-27 Advanced Accelerator Applications (Italy) Srl Prostate specific membrane antigen (PSMA) ligands and uses thereof
JP2023539990A (en) 2020-07-13 2023-09-21 ポイント バイオファーマ インコーポレイテッド Radiopharmaceuticals and methods
US11129912B1 (en) 2020-07-13 2021-09-28 POINT Biopharma Inc. Radiopharmaceutical and methods
CA3237590A1 (en) 2021-11-09 2023-05-08 James Basilion Psma targeted conjugate compounds and uses thereof

Also Published As

Publication number Publication date
WO2025022285A3 (en) 2025-03-06
CN121604981A (en) 2026-03-03
WO2025022285A2 (en) 2025-01-30
AU2024298619A1 (en) 2026-01-29
KR20260040237A (en) 2026-03-24

Similar Documents

Publication Publication Date Title
ZA202205794B (en) Once daily cancer treatment regimen with a prmt5 inhibitor
GB202016058D0 (en) Therapeautic treatment
GB202006390D0 (en) Novel treatments
GB202003722D0 (en) Treatment
IL310848A (en) Combination radiotherapy
CA3298914A1 (en) Psma-targeting radioligand treatment regimen
GB202212963D0 (en) Treatment regimen
GB202112635D0 (en) Treatment regimen
GB202019215D0 (en) Treatment regimen
GB202017853D0 (en) Treatment regimen
GB202008478D0 (en) Treatment regimen
GB202001514D0 (en) Treatment regimen
GB202018248D0 (en) ThermoHybrid cycle
GB202018400D0 (en) Treatment
GB202002711D0 (en) Treatment
CA212949S (en) Cycle
GB202117511D0 (en) Treatment regimens
GB202107075D0 (en) Cladribine regimen for treating nmosd
GB202116339D0 (en) Novel treatments
GB202112977D0 (en) Novel treatments
GB202112978D0 (en) Novel treatments
GB202112979D0 (en) Novel treatments
GB202112981D0 (en) Novel treatments
GB202112976D0 (en) Novel treatments
GB202112980D0 (en) Novel treatments